ChemicalBook > Product Catalog >API >Synthetic Anti-infective Drugs >Quinolones >Pazufloxacin


Pazufloxacin Suppliers list
Company Name: Henan DaKen Chemical CO.,LTD.
Tel: +86-371-66670886
Products Intro: Product Name:Pazufloxacin
Purity:99% Package:100g,500g,1kg,5kg,10kg
Company Name: Henan Tianfu Chemical Co.,Ltd.
Tel: 0371-55170693
Products Intro: CAS:127045-41-4
Purity:99% Package:500G;1KG;5KG;25KG
Company Name: career henan chemical co
Tel: +86-371-86658258
Products Intro: Product Name:Pazufloxacin
Purity:98% Package:1kg;2USD
Company Name: Hubei Jusheng Technology Co.,Ltd.
Tel: 86-18871470254
Products Intro: Product Name:Pazufloxacin
Purity:99% Package:5KG;1KG
Company Name: Chongqing Chemdad Co., Ltd
Tel: +86-13650506873
Products Intro: Product Name:Pazufloxacin
Purity:0.98 Package:1kg,2kg,5kg,10kg,25kg

Pazufloxacin manufacturers

  • Pazufloxacin USP/EP/BP
  • $1.10 / g
  • 2021-07-20
  • CAS:127045-41-4
  • Min. Order: 1g
  • Purity: 99.9%
  • Supply Ability: 100 Tons Min
  • Pazufloxacin
  • $15.00-10.00 / KG
  • 2021-07-13
  • CAS:127045-41-4
  • Min. Order: 1KG
  • Purity: 99%+ HPLC
  • Supply Ability: Monthly supply of 1 ton
  • Pazufloxacin
  • $15.00-10.00 / KG
  • 2021-07-10
  • CAS:127045-41-4
  • Min. Order: 1KG
  • Purity: 99%+ HPLC
  • Supply Ability: Monthly supply of 1 ton
Pazufloxacin Basic information
Description References
Product Name:Pazufloxacin
Synonyms:PAZUFLOXAXIN;T-3761;(s)-yclopropyl)-9-fluoro-3-methyl-7-oxo;Pazufloxacinmyesylate;(3S)-10-(1-AMINOCYCLOPROPYL)-9-FLUORO-2,3-DIHYDRO-3-METHYL-7-OXO-7H-PYRIDO[1,2,3-DE]-1,4-BENZOXAZINE-6-CARBOXYLIC ACID;ALKALYL;Pazufloxaxin mesilate;PAZUFLOXACIN 98+%
Product Categories:BacteriostaticAntibiotics;ChinolonesAlphabetic;PA - PENAnalytical Standards;Pharmacology Standards;Antibiotics;Chemical Structure;Chromatography;P;Principle;API's
Mol File:127045-41-4.mol
Pazufloxacin Structure
Pazufloxacin Chemical Properties
Melting point 269-271°C
alpha D25 -88.0° (c = 0.5 in 0.05N aq NaOH)
Boiling point 531.5±50.0 °C(Predicted)
density 1.56
storage temp. 2-8°C
form neat
CAS DataBase Reference127045-41-4(CAS DataBase Reference)
Safety Information
Hazard Codes Xn,C,F
Risk Statements 20/21/22-34-11
Safety Statements 36/37-45-36/37/39-26-16
WGK Germany 3
RTECS UU8815300
ToxicityLD50 i.v. in male mice: >500 mg/kg (Todo)
Pazufloxacin Usage And Synthesis
DescriptionPazufloxacin is a fluoroquinolone with a 1-aminocyclopropyl substituent at C10 position. The presence of aminoacyl group at C-10 is a unique feature of the molecule imparting potent broad spectrum activity against gram-positive and gram-negative bacteria. This activity is based on the inhibition of bacterial DNA gyrase.
Pazufloxacin is used as an injectable antibiotic with bacterial effect against cephalosporin-resistant, carbapenem-resistance, and aminoglycoside resistant strains of bacteria. The adverse effects of pazufloxacin, such as drug-induced convulsion and hypotension are less than those of other conventional injectable fluoroquinolones.
References[1] A. Vora, Pazufloxacin, tracked from on 16.07.2017
[2] Jeffrey K. Aronson, Meyler’s Side Effects of Antimicrobial Drugs, 2009
[3] Satoshi Watabe, Yoshiaki Yokoyama, Kazuyuki Nakazawa, Kimikazu Shinozaki, Rika Hiraoka, Kei Takeshita and Yukio Suzuki, Simultaneous measurement of pazufloxacin, ciprofloxacin, and levofloxacin in human serum by high-performance liquid chromatography with fluorescence detection, Journal of Chromatography B, 2010, vol. 878, 1555-1561
DescriptionPazufloxacin is a novel quinolone marketed for the treatment of bacterial infections in Japan. This tricyclic fluoro-quinolone can be synthesized in 11 steps from commercially available 2,3,4,5tetrafluorobenzoic acid. The cyclopropyl substituent is first introduced in 6 steps including 4-F-substitution with tert-butylcyanoacetate, decarboxylation, aa alkylation with 1 ,Zdibromoethane, partial nitrile hydrolysis and Hoffmann-rearrangement. The pyridoxazine ring is then introduced in 5 steps including 6-ketoester formation and pryridoxazine annulation. Pazufloxacin displays a broad spectrum activity against Grampositive and Gram-negative bacteria, although it is less active that ciprofloxacin against pneumococci and is not active against ciprofloxacin-resistant isolates. In patients with gonococcal urethritis a high prevalence of fluoroquinolone-resistant N. gonorrhoeae isolates with the Ser-91-to-Phe mutation in GyrA was observed. However, good clinical responses have been seen in clinical trials of patients with urinary tract infections and to a lesser extent with respiratory tract infections. Pazufloxacin is mainly excreted in urine with a short half-life (2-2.5 h). It has a phototoxicity equal to that of ciprofloxacin and its adverse effect profile resembles that of other quinolones.
OriginatorToyama (Japan)
Brand namePasil, Pazucross
Pharmaceutical ApplicationsA tricyclic fluoroquinolone, formulated as mesylate and hydrochloride salts for oral or parenteral use or as a methane sulfonate (eye ointment).
It displays good activity in vitro against methicillin susceptible Staph. aureus (MIC 0.2 mg/L), but is inactive against Str. pyogenes, Str. pneumoniae (MIC ≥4 mg/L) and enterococci. L. pneumophila is inhibited by 0.03 mg/L. Activity against Enterobacteriaceae, fastidious Gram-negative bacilli, Ps. aeruginosa and Acinetobacter spp. is similar to that of ofloxacin. It is weakly active against Sten. maltophilia and Burkholderia cepacia (MIC c. 2 mg/L). Against M. tuberculosis, MICs range from 0.8 to 4 mg/L. It is inactive against anaerobes.
After oral doses of 100 or 400 mg, peak plasma concentrations range from 0.94 mg/L (100 mg) to 4.5 mg/L (400 mg) after <1 h. The apparent elimination half-life is around 2 h. Most of the administered dose is eliminated in urine, about 70% within 24 h. Four metabolites have been reported. In elderly patients, according to the renal function, the peak plasma concentration may be elevated (up to 5.6 mg/L) and significantly delayed (2–6 h). The plasma protein binding ranges from 17% to 28%.
Tag:Pazufloxacin(127045-41-4) Related Product Information